Help
Subscribe


All of GastroHep is now free access! - Click here to register Read For FREE - Our full range of review articles
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Guido Tytgat Profile of Pete Peterson Profile of Peter Cotton Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Adalimumab plus immunosuppressors improve outcomes in Crohn's disease

December's issue of the Alimentary Pharmacology & Therapeutics investigates co-treatment with immunosuppressors improve outcome in patients with Crohn's disease treated with adalimumab.

News image

There is clear benefit from combination therapy with infliximab and immunosuppressive drugs, but few data are available for adalimumab.
 
Dr Reenaers and colleagues from Belgium assessed the efficacy of adalimumab monotherapy and adalimumab plus immunosuppressive drugs for induction and maintenance therapy in Crohn's disease.
 
Retrospective study of patients with Crohn's disease treated with adalimumab in the United Kingdom or Belgium.

Treatment periods were divided into 6-month semesters.

Successful induction was achieved in 83% of patients
Alimentary Pharmacology & Therapeutics

A combination therapy semester was defined as adalimumab plus immunosuppressive drugs for at least 3 months.

Successful induction meant clinical response, a semester with flare as adalimumab dose escalation, starting steroids, perianal complication, or surgery.

The team reported that adalimumab failure as adalimumab withdrawal for secondary loss of response or intolerance.

The researchers report successful induction in 83% of patients, with no significant difference between adalimumab +IS and adalimumab monotherapy.

The team included 562 semesters in 181 patients for maintenance analysis.

Adalimumab plus immunosuppressive drugs was not associated with fewer semesters with flare, or with adalimumab failure.

Nevertheless, combination therapy in the first semester was associated with a lower risk of adalimumab failure, and combination therapy beyond 6 months was associated with fewer semesters with flares.
 
Dr Reenaers' team concludes, "There may be a benefit from adalimumab plus immunosuppressive drugs combination therapy during the first semester of initiating adalimumab, with a slight decrease in adalimumab failure and lower need for adalimumab dosage escalation."

Aliment Pharmacol Ther 2012: 36(11pt12): 1040–1048
16 November 2012

Go to top of page Email this page Email this page to a colleague

 30 September 2014

Advanced search
 30 September 2014 
Medication use in patients with chronic Hep C
 30 September 2014 
Gastric cancer according to H pylori infection status
 30 September 2014 
Autoimmune hepatitis
 29 September 2014 
Peptic ulcer bleeding after PPI treatment
 29 September 2014 
Intestinal tuberculosis vs Crohn's disease
 29 September 2014 
Drug exposure and microscopic colitis
 26 September 2014 
Ondansetron for IBS with diarrhea
 26 September 2014 
5-aminosalicylates for the treatment of Crohn's
 26 September 2014 
Response to infliximab in paediatric perianal Crohn's
 25 September 2014 
Colorectal neoplasia among family members of patients with colorectal cancer
 25 September 2014 
Medical treatment and surgery rates in IBD
 25 September 2014 
Liver transplants for liver cancer
 24 September 2014 
PPIs after antireflux surgery
 24 September 2014 
Antidepressants in chronic liver disease
 24 September 2014 
Health services burden of IBD
 23 September 2014 
Upper GI bleeding with drug combinations
 23 September 2014 
Recurrence of Barrett's neoplasia after resection
 23 September 2014 
Abnormal prion protein in appendixes
 22 September 2014 
Anorectal function after low anterior resection
 22 September 2014 

Anorectal stricture in Crohn's

 22 September 2014 
Malignancies in celiac disease
 19 September 2014 
Adhesions in abdominal and pelvic surgery
 19 September 2014 
Repeat colonoscopy among US Medicare
 19 September 2014 
Progression to liver cancer in HCV-infected Veterans
 18 September 2014 
Patient improvement following sacral neuromodulation
 18 September 2014 
Autoimmune diseases in functional gastrointestinal disorders
 18 September 2014 
New diagnostic score for hepatic steatosis
 17 September 2014 
Orange juice intake for bowel preparation
 17 September 2014 
Treatment of fistulising perianal Crohn's disease
 17 September 2014 
Interval colorectal cancers
 16 September 2014 
Fiber treats IBS
 16 September 2014 
Resected biliary tract cancer
 16 September 2014 
Postoperative adhesions in digestive surgery
 15 September 2014 
Fecal transplantation for C.diff infection
 15 September 2014 
Prunes and GI function
 15 September 2014 
Antidepressants for IBS
 12 September 2014 
Metabolic syndrome delays HBeAg seroclearance
 12 September 2014 
Drug-induced liver disease
 12 September 2014 
Management of complex colon polyps
 11 September 2014 
Sofosbuvir plus peginterferon/ribavirin for HCV
 11 September 2014 
Hepatobiliary cirrhosis risk after organ transplant
 11 September 2014 
Patient perceptions in celiac disease
 10 September 2014 
Acute kidney injury after colonoscopy
 10 September 2014 
Management algorithm for endoscopic mucosal resection of colonic lesions
 10 September 2014 
Adhesions in abdominal and pelvic surgery
 09 September 2014 
Neutrophil function and mortality in cirrhosis
 09 September 2014 
PPIs and spontaneous bacterial peritonitis in cirrhosis
 09 September 2014 
MELD and liver cancer survival
 08 September 2014 
Comparison of diet programs in overweight and obese adults
 08 September 2014 
Vagal nerve blockade and morbid obesity
 08 September 2014 
Long-term follow-up after bariatric surgery
 05 September 2014 
Healing rates in reflux esophagitis
 05 September 2014 
Progression of environmental enteropathy
 05 September 2014 
Diabetes and liver transplant outcomes
 04 September 2014 
Colectomy rates for refractory ulcerative colitis
 04 September 2014 
Infliximab prevents long-term Crohn’s disease recurrence
 04 September 2014 
Histological recovery with gluten-free diet in celiac disease
 03 September 2014 
Predictors of response in Crohn's disease
 03 September 2014 
Diagnosis of atrophic gastritis
 03 September 2014 
Safety of reinitiation of infliximab therapy

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2014 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us